Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by princeofcuton May 04, 2015 10:28am

142 Views

Post# 23690986

RE:RE:A CHINA TRIAL FOR BET ON MACE?

for the honest non-fraudster and scumbag posters on this MB (leftcoast, big fat wieny, hoity toity, etc.) go to this link and download the whitepaper...amongst interesting comments, it can take over a year to get a trial approved in China, their regulatory regime is more complex than US, diabetes is the focus of most trials, anyways here is the link: lsconnect.thomsomreuters.com/overcoming-clinical-challenges-china or just search the over.... regards

Bullboard Posts

First Helium advances winter drilling program with Leduc Anomaly test well